Comment
Precision medicine in COPD exacerbations

https://doi.org/10.1016/S2213-2600(18)30296-0Get rights and content

First page preview

First page preview
Click to open first page preview

References (15)

  • VM Pinto-Plata et al.

    Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD

    Chest

    (2007)
  • CF Vogelmeier et al.

    Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary

    Am J Respir Crit Care Med

    (2017)
  • WC Tan et al.

    Exacerbation-like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results from a population-based study

    Thorax

    (2014)
  • B Beghé et al.

    Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD

    Eur Respir J

    (2013)
  • G Scioscia et al.

    Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations

    Thorax

    (2017)
  • M Bafadhel et al.

    Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers

    Am J Respir Crit Care Med

    (2011)
  • JL Jameson et al.

    Precision medicine—personalized, problematic, and promising

    N Engl J Med

    (2015)
There are more references available in the full text version of this article.

Cited by (22)

  • [Translated article] ANTES Program: One Year on

    2022, Archivos de Bronconeumologia
  • ANTES Program: One Year on

    2022, Archivos de Bronconeumologia
  • Goals of COPD treatment: Focus on symptoms and exacerbations

    2020, Respiratory Medicine
    Citation Excerpt :

    Pulmonary inflammation varies greatly between individuals, and this has proven challenging in terms of biomarker evaluation or inflammation-targeted therapeutic intervention [56]. Unlike COPD exacerbations [57], other acute presentations of chronic diseases (e.g. myocardial infarction) have specific and sensitive diagnostic toolkits, such as biomarkers and imaging techniques, that are used in routine management of patients [56]. Exacerbations can also be difficult to recognize, and many patients presenting with a COPD exacerbation have comorbid conditions, which complicates evaluation and management.

  • Biomarkers of DNA damage in COPD patients undergoing pulmonary rehabilitation: Integrating clinical parameters with genomic profiling

    2019, Mutation Research - Genetic Toxicology and Environmental Mutagenesis
    Citation Excerpt :

    The comprehensive understanding of the genomic profile is a critical step forward for the construction of a personalized therapeutic approach and will make the difference within the rehabilitative framework as a fundamental tool for the recovery of disability and the improvement of quality of life (QoL). The recent precision medicine approach, the so called ‘Rehabilomics’, represents a translational framework for programs of personalized rehabilitation, focused on linking personal biology to the bio-psychosocial constructs [32–36]. In this paper we will investigate in a group of COPD patients those variables that may predict the response to a program of pulmonary rehabilitation (PR), integrating clinical parameters with cellular and molecular measurements, offering the potential for more effective and individualized treatment options.

View all citing articles on Scopus
View full text